12 Apr
  • By Debra Miller
  • Cause in

CureDuchenne Shares Pfizer’s Update Regarding Initiation of Gene Therapy Trial

Today, Pfizer announced that the first patient was dosed in their mini-dystrophin gene therapy trial.  This is an exciting day for the Duchenne community.  Pfizer has the experience to conduct this trial, and manufacturing capacity to see it through to success.  Of course, this is an early stage safety trial and there is a long […]

READ MORE
01 Aug
  • By leilanifera
  • Cause in

Bamboo Therapeutics

Approach: Gene therapy for Duchenne
Funding Impact: Accelerated vector manufacturing capabilities
Successful Exit: Acquired by Pfizer in August 2016

READ MORE